RESEARCH PAPER
Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation.
AI Summary
The paper reports that the SGLT2 inhibitor dapagliflozin reduces motor deficits in a 6‑OHDA Parkinson’s model and, through combined in vivo and in silico work, implicates modulation of α‑synuclein, A2A receptor, TH, TNF‑α and intrinsic apoptosis (APAF‑1/caspase‑3) pathways.
Why It Matters
This suggests a repurposing opportunity for an approved diabetes drug with anti‑inflammatory and anti‑apoptotic effects relevant to PD biology, improving translational potential despite limitations of the acute 6‑OHDA model and the missing abstract for full assessment.
